目的 了解亳州市人民醫(yī)院使用依達(dá)拉奉右莰醇注射用濃溶液的情況，為規(guī)范臨床合理應(yīng)用提供依據(jù)。方法 回顧性隨機(jī)抽取2022年9月—2023年2月在亳州市人民醫(yī)院使用依達(dá)拉奉右莰醇注射用濃溶液150份患者病歷，從適應(yīng)證、用法用量、使用療程、禁忌證等方面進(jìn)行合理性評(píng)價(jià)。結(jié)果 150份病歷中，用藥不合理病歷共計(jì)70份（46.67%），其中超適應(yīng)證用藥30份（20.00%）、超醫(yī)保支付限制適應(yīng)證用藥33例（22.00%）、給藥劑量不適宜31份（20.67%）、給藥頻次不適宜4份（2.67%）、超療程用藥3份（2.00%）、用藥時(shí)機(jī)不適宜3份（2.00%）、溶媒劑量不適宜9份（6.00%）和超禁忌癥用藥1份（0.67%）。結(jié)論 依達(dá)拉奉右莰醇注射用濃溶液在臨床使用存在超適應(yīng)證用藥、劑量不適宜、超療程用藥等不合理問題，應(yīng)引起臨床藥師和醫(yī)生高度重視，促進(jìn)合理用藥。

Objective To investigate the use of Edaravone and Dexborneol Concentrated Solution for injection in Bozhou People's Hospital, and to provide basis for clinical rational application. Methods The medical records of 150 patients who used Edaravone and Dexborneol Concentrated Solution for injection in the Bozhou People's Hospital from September 2022 to February 2023 were randomly selected retrospectively, and the rationality was evaluated from the indications, dosage, course of treatment, contraindications. Results Among the 150 medical records, 70 cases (46.67%)were unreasonable. Among them, there were 30 cases (20.00%) of off-label drug use, 33 cases (22.00%) of drugs used for indications beyond the payment limit of medical insurance, 31 cases (20.67%) of inappropriate dose, 4 cases (2.67%) of inappropriate frequency of drug administration, 3 cases (2.00%) of excessive drug use, 3 (2.00%) cases of inappropriate timing of drug use, 9 cases (6.00%) of inappropriate solvent dose, and 1 case (0.67%)was super-contraindications. Conclusion There are unreasonable problems in the clinical use of Edaravone and Dexborneol Concentrated Solution for injection, such as over-indication, inappropriate dose, over-treatment and so on. Clinical pharmacists and doctors should pay high attention to it and promote rational use of drugs.

R971